Related references
Note: Only part of the references are listed.Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Disease activity return after natalizumab cessation in multiple sclerosis
Maria Rasenack et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Disease activity return after natalizumab cessation in multiple sclerosis
Maria Rasenack et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
Nicholas Schwab et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
Pietro Iaffaldano et al.
BRAIN (2015)
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation
Benjamin Berger et al.
JOURNAL OF NEUROIMMUNOLOGY (2015)
Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS
Ludwig Kappos et al.
NEUROLOGY (2015)
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment
Simon Faissner et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
Per Soelberg Sorensen et al.
JOURNAL OF NEUROLOGY (2014)
Fingolimod after natalizumab and the risk of short-term relapse
Vilija G. Jokubaitis et al.
NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen et al.
JAMA NEUROLOGY (2014)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
